Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Mary Remington who wrote (206)	1/13/1998 11:14:00 AM
From: Harry D. Kramer	Read Replies (1) \| Respond to of 1510

Mary, I expect a deal in one of its gene therapy programs. They already have a major collaboration with Bayer in the development of gene therapy products for the treatment of hemophilia A. The company's gene therapy programs for hepatitis B and atherosclerosis, however, are still without a partner. I don't think that IMNR wants to carry these through the clinic on its own. Further out, an expansion of the Bayer collaboration is possible. A deal in the autoimmune disease area is also a possibility, but I don't expect one in the next few months. And I would definitely be surprised to see a marketing deal for Remune before the interim data release in the 2nd quarter. Regards, Harry